Cancer Therapeutics Market - 2024-2032
The Cancer Therapeutics Market was valued at US$ 168.15 billion in 2024 and is anticipated to reach US$ 491.60 billion by 2032, at a CAGR of 0.126 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Therapeutics Market.
This report delivers a comprehensive overview of the Cancer Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Therapeutics Market. The Cancer Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.
Cancer Therapeutics Market Scope:
By Therapy
This report delivers a comprehensive overview of the Cancer Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Therapeutics Market. The Cancer Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Therapeutics Market.
This report delivers a comprehensive overview of the Cancer Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Therapeutics Market. The Cancer Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.
Cancer Therapeutics Market Scope:
By Therapy
- Targeted Therapy
- Hormonal Therapy
- Chemotherapy
- Radiotherapy
- Immunotherapy
- Others (Photodynamic Therapy, Others)
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Blood Cancer
- Cervical Cancer
- Malignant Meningioma
- Head and Neck Cancer
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Hospitals
- Cancer Centers
- Research Institutes
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Astellas Pharma Inc.
- Pfizer, Inc.
- Novartis AG
- Merck & Co., Inc.
- Eli Lilly and Company
- Amgen Inc.
- AstraZeneca
This report delivers a comprehensive overview of the Cancer Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Therapeutics Market. The Cancer Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Therapy
3.2. Snippet by Cancer Type
3.3. Snippet by Distribution Channel
3.4. Snippet by End-User
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of cancers globally
4.1.2. Restraints
4.1.2.1. Presence of generic drugs
4.1.3. Opportunity
5. IMPACT ANALYSIS
6. INDUSTRY ANALYSIS
6.1. Porter’s Five Force Analysis
6.2. Supply Chain Analysis
6.3. Pricing Analysis
6.4. Patent Analysis
6.5. Regulatory Analysis
6.6. SWOT Analysis
6.7. Unmet Needs
7. BY THERAPY
7.1. Introduction
7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.1.2. Market Attractiveness Index, By Therapy
7.2. Targeted Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Hormonal Therapy
7.4. Chemotherapy
7.5. Radiotherapy
7.6. Immunotherapy
7.7. Others (Photodynamic Therapy, Others)
8. BY CANCER TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.1.2. Market Attractiveness Index, By Cancer Type
8.2. Breast Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Lung Cancer
8.4. Prostate Cancer
8.5. Blood Cancer
8.6. Cervical Cancer
8.7. Malignant Meningioma
8.8. Head and Neck Cancer
8.9. Others
9. BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Others
10. BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cancer Centers
10.4. Research Institutes
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY
12.1. U.S.
12.1.1. Canada
12.1.1.1. Mexico
12.2. Europe
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. Germany
12.2.7.2. U.K.
12.2.7.3. France
12.2.7.4. Spain
12.2.7.5. Italy
12.2.7.6. Rest of Europe
12.3. South America
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Brazil
12.3.7.2. Argentina
12.3.7.3. Rest of South America
12.4. Asia-Pacific
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. China
12.4.7.2. India
12.4.7.3. Japan
12.4.7.4. South Korea
12.4.7.5. Rest of Asia-Pacific
12.5. Middle East and Africa
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. COMPANY PROFILES
14.1. F. Hoffmann-La Roche AG*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Bristol-Myers Squibb Company
14.3. AbbVie Inc.
14.4. Astellas Pharma Inc.
14.5. Pfizer, Inc.
14.6. Novartis AG
14.7. Merck & Co., Inc.
14.8. Eli Lilly and Company
14.9. Amgen Inc.
14.10. AstraZeneca (LIST NOT EXHAUSTIVE)
15. APPENDIX
15.1. About Us and Services
16. CONTACT US
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Therapy
3.2. Snippet by Cancer Type
3.3. Snippet by Distribution Channel
3.4. Snippet by End-User
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of cancers globally
4.1.2. Restraints
4.1.2.1. Presence of generic drugs
4.1.3. Opportunity
5. IMPACT ANALYSIS
6. INDUSTRY ANALYSIS
6.1. Porter’s Five Force Analysis
6.2. Supply Chain Analysis
6.3. Pricing Analysis
6.4. Patent Analysis
6.5. Regulatory Analysis
6.6. SWOT Analysis
6.7. Unmet Needs
7. BY THERAPY
7.1. Introduction
7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.1.2. Market Attractiveness Index, By Therapy
7.2. Targeted Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Hormonal Therapy
7.4. Chemotherapy
7.5. Radiotherapy
7.6. Immunotherapy
7.7. Others (Photodynamic Therapy, Others)
8. BY CANCER TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.1.2. Market Attractiveness Index, By Cancer Type
8.2. Breast Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Lung Cancer
8.4. Prostate Cancer
8.5. Blood Cancer
8.6. Cervical Cancer
8.7. Malignant Meningioma
8.8. Head and Neck Cancer
8.9. Others
9. BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Others
10. BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cancer Centers
10.4. Research Institutes
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY
12.1. U.S.
12.1.1. Canada
12.1.1.1. Mexico
12.2. Europe
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. Germany
12.2.7.2. U.K.
12.2.7.3. France
12.2.7.4. Spain
12.2.7.5. Italy
12.2.7.6. Rest of Europe
12.3. South America
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Brazil
12.3.7.2. Argentina
12.3.7.3. Rest of South America
12.4. Asia-Pacific
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. China
12.4.7.2. India
12.4.7.3. Japan
12.4.7.4. South Korea
12.4.7.5. Rest of Asia-Pacific
12.5. Middle East and Africa
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. COMPANY PROFILES
14.1. F. Hoffmann-La Roche AG*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Bristol-Myers Squibb Company
14.3. AbbVie Inc.
14.4. Astellas Pharma Inc.
14.5. Pfizer, Inc.
14.6. Novartis AG
14.7. Merck & Co., Inc.
14.8. Eli Lilly and Company
14.9. Amgen Inc.
14.10. AstraZeneca (LIST NOT EXHAUSTIVE)
15. APPENDIX
15.1. About Us and Services
16. CONTACT US
